Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

An inexpensive antifungal drug, thiabendazole (see structure), slows tumor growth and shows promise as a chemotherapy for cancer. Scientists in the College of Natural Sciences at The University of Texas at Austin made this discovery by exploiting the evolutionary relatedness of yeast, frogs, mice and humans.

Thiabendazole is an FDA-approved, generic drug taken orally that has been in clinical use for 40 years as an antifungal. It is not currently used for cancer therapy.....

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

USPTO issues patent to MicuRx’s MRX-I antibacterial agent

USPTO issues patent to MicuRx’s MRX-I antibacterial agent: MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone (general structure of 2-oxazolidinone) that targets infections due to multi-drug resistant Gram-positive pathogens.